Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13vPnC When Administered to Healthy Japanese Adults Aged >= 65 Years and 50 to 64 Years in Japan Who Have Not Received a Previous Dose of 23-Valent Pneumococcal Polysaccharide Vaccine

NCT00562354 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00562354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00562354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a 13vPnC When Administered to Healthy Japanese Adults Aged >= 65 Years and 50 to 64 Years in Japan Who Have Not Received a Previous Dose of 23-Valent Pneumococcal Polysaccharide Vaccine
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
October 31, 2007
Completion date
December 31, 2007
Enrollment
271 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy